MHIF Cardiovascular Grand Rounds | May 20, 2024







Aortitis, a Serious Diagnosis with Rare Etiologies

Nedaa Skeik, MD, FACC, FACP, FSVM, RPVI

Professor of Medicine Section Head, Vascular Medicine Medical Director, Thrombophilia/Anticoagulation Clinic Medical Director, Vascular Laboratories Medical Director, Vein Center Minneapolis Heart Institute® - Abbott Northwestern Hospital

Disclosures
 Speaking and consulting for Janssen, Novo Nordisk, and Lexicon (not relevant).
 No financial conflict related to this talk.
 Some of the cases were modified for teaching purposes.
3 MINNEAPOLIS Alina Healthŵ Heart ABBOTT INSTITUTE NORTHWESTERN HOSPITAL









```
7
```





9	9	1	r		۱	
2	2					
-	-	4		4	,	

















Steroid Sparing Agents		
 Tocilizumab: IL6 inhibitor, first FDA-approved drug for GCA! Decreased rate of first relapse 		
 Significant reduction in the cumulative dose of glucocorticoids 162 mg SC qwk for a year 		
 When to start and stop?! New data: taper; weekly for 12 and then bi-weekly for another 12 months How soon should prednisone be tapered? (3-4 months)! 		
Methotrexate: at best, is only moderately effective!		
Abatacept: CD4+ inhibitor, borderline effective		
• Ustekinumab: IL-12 (Th1) IL-23 (Th17) inhibitor, promising results		
DMARDs: Azathioprine, cyclophosphamide, leflunomide		
TNF inhibitors: not that effective!	MINNEAPOUS	
Villiger PM et al. Lancet 2016; 387:1921 18 Skeik et al. Vasc Endovascular Surgery 20017 Oct;51(7):470-479	HEART INSTITUTE	ABBOTT NORTHWESTERN HOSPITAL



```
19
```





















<section-header><section-header><complex-block><complex-block>







<section-header><complex-block><complex-block>







```
37
```







Study	Location	Туре І	Type Ila	Type llb	Type III	Type IV	Type V
Singh et al. (2015) ¹⁶	India	32.2%	8.1%	1.6%	3.2%	17.7%	37.1%
Schmidt et al. (2013) ¹⁵	United States	20%	6%	7%	5%	5%	57%
Sahin et al. (2012) ¹⁷	Turkey	39.4%	6.4%	2.7%	3.9%	4.5%	43%
Cong et al. (2010) ¹⁸	China	40%	4.8%	1.6%	2.4%	20.8%	30.4%
Kechauo et al. (2009) ¹⁹	Tunisia	67.7%	0%	10.7%	0%	3.6%	25%
Petrovic-Rackov et al.	Serbia	50%	19%	0%	0%	0%	31%
(2009) ²⁰							
Park et al. (2005) ²¹	South Korea	36.1%	2.8%	4.6%	7.4%	15.8%	33.3%
Sato et al. (1998) ²²	Brazil	21%	4%	0%	4%	14%	57%
Suwanwela et al. (1996) ²³	Thailan	0%	0%	11.1%	3.2%	19%	66.7%



Takayasu Manageme	nt	
Prednisone: initial dose 40-60 mg daily		
Slow taper: no faster than 10 mg a week when improve		
 Steroids sparing or resistant patients: DMARDs (Methotrexate, azathuiopirine or leflunomide): effective Anti-TNF agents: etanercept, adalimumab or infliximab are effective IL-6 inhibitor: Tocilizumab, based on study cohorts (CRT: low number!) 		
 Revascularization: when disease is inactive! Patency in 9.4 years: Open: 79% Endo 52% Failure can be reduced by medical therapy Bredemeler M, et al. Clin Exp Rheumatol 2012; 30:598 	Minneapolis Heart	Alina Health % ABBOTT
Hoffman GS et al Arthritis Rheum 2004; 50:2296. BJS 2014;101:43-50	Institute	NORTHWESTERN HOSPITAL





CASE: 3
 Presentation: 51 y.o. M. presented with 2 wks of fever, night sweats and chest pain. Exam: friction rub, erythematous rash all four extremities
• Labs: WBC: 17.1, Hgb: 10.4, ESR: 96, CRP 24.28, and normal troponin
 CXR: cardiomegaly EKG: AV flutter TTE: LV EF 30%, moderate pericardial effusion, thickened enlarged ascending aorta 6.5 cm
45 MINNEAPOLIS Alima Health & Heart INSTITUTE NORTHWESTERN HOSPITAL





<section-header><section-header><section-header><image><image><image>

ANA positive C-ANCA (PR3-ANCA) strongly positive: > 1:160 RF positive: 33.3 (Normal < 15.9) Rest of rheumatology work up was negative including IgG4 level Chest CT: diffuse mediastinal lymph node prominence PET scan: increased uptake around the ascending and abdominal aorta Multiple sets of blood cultures: negative Skin biopsy: perivascular neutrophilic infiltrate (nonspecific!)





CASE 3: Final Diagnosis: C-ANCA (PR3-ANCA) Vasculitis

- ANCA associated vasculitis (AAV): necrotizing small vessel vasculitis
- C-ANCA (PR3- ANCA) : Granulomatosis with polyangiitis
- P-ANCA (MPO-ANCA): Microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, or renal-limited vasculitis

• ACR Criteria for diagnosis of GPA:

- Nasal or oral inflammation
- Abnormal chest radiograph showing nodules, fixed infiltrates, or cavities
- Abnormal urinary sediment (microscopic hematuria)
- Granulomatous inflammation on biopsy of an artery or perivascular area
- Management: Glucocorticoids combined with rituximab, or less favorably with cyclophosphamide.

Skeik N et al. Rheumatol Int. 2019 Nov;39(11):1983-1988.



Allina Health 🕷 ABBOTT NORTHWESTERN HOSPITAL



53







Jaga Related Disease Diagnosis and Treatment Diagnosis • Clinical: classic organ involvement • Serology: elevated serum IgG4, depressed C3/C4 • Radiology: periaortitis, sausage-shaped pancreas • Pathology: classic pathology and positive stain for IgG4 • Prednisone: initial dose 40 mg po daily • Rituximab: as a sparing agent or in resistant cases

	CASE: 5
•	Presentation: 55 y.o. M. with hx of HTN presents with abdominal and left flank pain that radiates to the groin area
•	Physical exam:
-	Periumbilical and left flank moderate tenderness
• - -	Labs and Images: WBC 11.6, Hgb: 10.5 Creatinine 3.2 ESR: 80, CRP 4.6
-	Abdominal ultrasound: left side hydronephrosis
•	Rest of autoimmune work up as well as blood cultures are negative
58	MINNEAPOLIS HEART INSTITUTE ABBOTT NORTHWESTERN HOSPITAL
58	









 Multisystem non-Langerhans cell histiocytosis Periadventitial infiltrate can mimic: IgG4-RD, TAK, GCA 	Frequency of clinical or r characteristics in Erdheim	adiologic ı - Chester
BRAF V600E in approximately half of cases	Osteosclerosis *	96%
 Work Up: Biopsy: non-Langerhans histocytosis BRAF V600E Some cases with elevated ESR and CRP Imaging: Hairy kidney/Coated aorta Management: 	Bone Pain *^ CNS Involvement *# Diabetes Insipidus *^# Exophthalmos *^ Xanthelasmas *^ Cardiac Involvement *^ Pulmonary Involvement *^ Periaortic Infiltration *^#	40-50% 15-51% 25-27% 24-32% 19-28% 42-52% 22-43% 60-66%
- BRAF V600E (+): Vemurafenib, Dabrafenib	"Coated Aorta" *#	23-30%
- BRAF V600E (-): Steroids, IFN-α, anakinra tocilizumab, infliximab	"Hairy Kidney" *	68%

CASE: 7
Presentation: 59 y.o man with hx of obesity and HTN, presented with abdominal pain
Exam:

Periumbilical moderate tenderness

Labs:

ESR 34 and CRP 2.72
CBC and CMP are unremarkable
Extensive unremarkable rheumatological work up
Negative multiple blood cultures







<text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><table-container><table-container><list-item><list-item><list-item><list-item></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row>









		METH	HODS			
	Takayasu Arteritis	Giant Cell Arteritis	IgG4-related systemic disease	Inflammatory Idiopathic Aortitis		
	Criteria (3 or more): ²³	Criteria (3 or more):29	Criteria (all) ^{6,7} Diffuse or local	Based on exclusion		
	Age at onset: <40	Age at onset: ≥ 50	swelling, masses, or	(criteria for other		
	years Claudication of extremities	years New headache	thickness in single or multiple organs Characteristic histopathological appearance (dense lymphoplasmacytic infiltrate, fibrosis, obliterative phlebitis)	diagnoses are not met)		
	Decreased brachial artery pulse	Temporal artery abnormality	Increased numbers of IgG4 ⁺ plasma cells or IgG4 ⁺ /IgG ⁺ plasma cell ratio of >40%			
	Blood pressure difference >10 mm Hg Bruit over subclavian arteries or aorta Arteriogram abnormality	Elevated erythrocyte sedimentation rate Abnormal artery biopsy				
Table 1: Clinical cri 73 Skeik et al Vasc Endovascular Surg. 2017 Oct	iteria used to categori t;51(7):470-479	ze patients with aortit	is	ier	Minneapolis Heart Institute	Alina Health 🖮 ABBOTT NORTHWESTERN HOSPITAL



DEC			aulation	
KES	OLIS.	Sludy Po	pulation	
	All aortitis (n=15)	Takayasu arteritis (n=8)	Inflammatory idiopathic aortitis (n=5)	Giant cell arteritis (n=2)
Age (years), mean (SD)	51 (17)	41 (17)	57 (4)	75 (8)
Race				
Caucasian, (%)	8 (53)	5 (63)	1 (20)	2 (100)
Hispanic, (%)	1 (7)	1 (13)	0 (0)	0 (0)
Asian, (%)	3 (13)	1 (13)	2 (40)	0 (0)
African American, (%)	3 (13)	1 (13)	2 (40)	0 (0)
Male, (%)	4 (27)	1 (13)	3 (60)	0 (0)
BMI, mean (SD)	25 (5)	23 (5)	28 (3)	24 (8)
History of Tobacco Use, (%)	6 (40)	1 (13)	4 (80)	1 (50)
Current Tobacco Use, (%)	2 (13)	0 (0)	2 (40)	0 (0)
Diabetes Mellitus, (%)	2 (13)	1 (13)	1 (20)	0 (0)
Hypertension, (%)	6 (40)	3 (38)	1 (20)	2 (100)
Hyperlipidemia, (%)	5 (33)	3 (38)	2 (40)	0 (0)
Peripheral arterial disease, (%)	1 (7)	1 (13)	0 (0)	0 (0)
Autoimmune disease				
Rheumatoid Arthritis, (%)	1 (7)	0 (0)	0 (0)	1 (50)
Dvascular Surg. 2017 Oct;51(7):470	179		ite	Minneapolis Heart Institute

	All aortitis (n=15)	Takayasu arteritis (n=8)	Inflammatory idiopathic aortitis (n=5)	Giant cell arteritis (n=2)
Age (years), mean (SD)	51 (17)	41 (17)	57 (4)	75 (8)
Race				
Caucasian, (%)	8 (53)	5 (63)	1 (20)	2 (100)
Hispanic, (%)	1 (7)	1 (13)	0 (0)	0 (0)
Asian, (%)	3 (13)	1 (13)	2 (40)	0 (0)
African American, (%)	3 (13)	1 (13)	2 (40)	0 (0)
Male, (%)	4 (27)	1 (13)	3 (60)	0 (0)
BMI, mean (SD)	25 (5)	23 (5)	28 (3)	24 (8)
History of Tobacco Use, (%)	6 (40)	1 (13)	4 (80)	1 (50)
Current Tobacco Use, (%)	2 (13)	0 (0)	2 (40)	0 (0)
Diabetes Mellitus, (%)	2 (13)	1 (13)	1 (20)	0 (0)
Hypertension, (%)	6 (40)	3 (38)	1 (20)	2 (100)
Hyperlipidemia, (%)	5 (33)	3 (38)	2 (40)	0 (0)
Peripheral arterial disease, (%)	1 (7)	1 (13)	0 (0)	0 (0)
Autoimmune disease				
Rheumatoid Arthritis, (%)	1 (7)	0 (0)	0 (0)	1 (50)

RES	ULTS:	Study Po	pulation	า	
	All aortitis (n=15)	Takayasu arteritis (n=8)	Inflammatory idiopathic aortitis	Giant cell arteritis (n=2)	
Age (years), mean (SD)	51 (17)	41 (17)	57 (4)	75 (8)	
Bace					
Caucasian, (%)	8 (53)	5 (63)	1 (20)	2 (100)	
Asian, (%)	3 (13)	1 (13)	2 (40)	0 (0)	
African American, (%) Male. (%)	3 (13)	1 (13)	2 (40) 3 (60)	0 (0)	
BMI, mean (SD)	25 (5)	23 (5)	28 (3)	24 (8)	
History of Tobacco Use, (%)	6 (40)	1 (13)	4 (80)	1 (50)	
Current Tobacco Use, (%)	2 (13)	0 (0)	2 (40)	0 (0)	
Diabetes Mellitus, (%)	2 (13)	1 (13)	1 (20)	0 (0)	
Hypertension, (%)	6 (40)	3 (38)	1 (20)	2 (100)	
Hyperlipidemia, (%)	5 (33)	3 (38)	2 (40)	0 (0)	
Peripheral arterial disease, (%)	1 (7)	1 (13)	0 (0)	0 (0)	
Autoimmune disease	4 (7)	0.(0)	0 (0)	4 (50)	
Rheumatoid Arthritis, (%)	1(/)	0 (0)	0(0)	1 (50)	
			L.C.	Minneapolis Heart Institute	ABE

Patient baseline clinical and laboratory characteristics	All aortitis	Takayasu arteritis	Idiopathic inflammatory aortitis	Giant cell arteritis
	(n=15)	(n=8)	(n=5)	(n=2)
Length of hospital stay (days), median (25 th , 75 th percentile)	2 (0, 4.5)	0 (0, 0.5)	3 (2, 5)	7.5 (5.8, 9.3)
Systemic Complaints (%)	7 (47)	5 (63)	2 (40)	0 (0)
Type of imaging				
MRA, (%)	8 (53)	5 (63)	2 (40)	1 (50)
CTA, (%)	6 (40)	3 (38)	2 (40)	1 (50)
PET, (%)	1 (7)	0 (0)	1 (20)	0 (0)
Location of inflammation				
Thoracic, (%)	6 (40)	4 (50)	0 (0)	2 (100)
Abdominal, (%)	6 (40)	2(25)	4 (80)	0 (0)
Thoracoabdominal (%)	3 (20)	2 (25)	1 (20)	0 (0)
Stenosis	9 (60)	6 (75)	2 (40)	1 (50)
Thoracic, (%)	5 (33)	4 (50)	0 (0)	1 (50)
Abdominal, (%)	2 (13)	2 (25)	0 (0)	0 (0)
Cerebrovascular, (%)	2 (13)	2 (25)	0 (0)	0 (0)
Upper extremity, (%)	6 (40)	5 (62)	0 (0)	1 (50)
Lower extremity, (%)	2 (13)	1 (13)	2 (40)	
Occlusion	5 (33)	4 (50)	0 (0)	1 (50)
Thoracic, (%)	1 (7)	0 (0)	0 (0)	1 (50)
Upper extremity, (%)	3 (20)	3 (38)	0 (0)	0 (0)
Aneurysm	6 (40)	3 (38)	2 (40)	1 (50)
Thoracic, (%)	3 (20)	2 (25)	0 (0)	1 (50)
Abdominal, (%)	2 (13)	0 (0)	2 (40)	0 (0)
ESR				
Normal, (%)	4 (29)	2 (25)	2 (40)	0 (0)
High, (%)	10 (71)	6 (75)	3 (60)	1 (100)
CRP				
Normal, (%)	2 (15)	1 (14)	1 (20)	0 (0)
High, (%)	11 (85)	6 (86)	4 (80)	1 (100)
C-ANCA				
Positive, (%)	1 (14)	0 (0)	1 (25)	
Negative, (%)	6 (86)	3 (100)	3 (75)	
P-ANCA				
Positive, (%)	1 (14)	1 (33)	0 (0)	
Negative, (%)	6 (86)	2 (67)	4 (100)	
IgG4				
Normal, (%)	5 (100)	2 (100)	3 (100)	
	- ()	4 (50)	1 (20)	2 (100)

Aortiti	Aortitis Management Regimen							
	All aortitis (n=15)	Takayasu arteritis (n=8)	Inflammatory idiopathic aortitis (n=5)	Giant cell arteritis (n=2)				
Steroids, (%)	15 (100)	8 (100)	5 (100)	2 (100)				
Other immunosuppressants/ modulators, (%)	10 (67)	6 (75)	4 (80)	0 (0)				
Surgical Intervention,(%)	5 (33)	4 (50)	0 (0)	1 (50)				
Endovascular Surg. 2017 Oct:51(7):470-479			Ű	Minneapolis Ali Heart AB Institute NC HC				

Indications, Outcomes, and Complications of Interventional Procedures

Patient	Indication for Procedure	Type of Procedure	Procedure	Complication		
			Outcome			
2	Course standsig of left main conserve artery	Covenery extern by see crefting	Sussaaful	NI/A		
2	Severe stenosis of left main coronary artery	Coronary artery bypass granting	Successiui	N/A		
4	Severe stenosis and thromhosis of hilateral common iliac artery	Aspiration thrombectomy, bilateral drug-eluting balloon	Successful	Right iliac artery dissection		
-	Severe stenosis and thrombosis of bilateral common mac artery	Aspiration thrombectomy, bhateral drug-eldting balloon	Juccessiui	Right mac artery dissection		
		angioplasty, left stenting				
0	Course standing of vight your lasters, induced	Austaulasty and stanting of the yight yous lastery	Cussosoful	NI/A		
9	Severe stenosis of right renar artery, induced	Angioplasty and stenting of the right renai artery	Successiui	N/A		
	nypertension					
		NUL 11 11 11 11 11 11 11 11 11				
	Symptomatic severe stenosis of bilateral	Balloon angioplasty and stenting of bilateral subclavian	Successful	Right subclavian artery re-stenosis		
	subclavian artery	artery				
11	Aortic valve insufficiency	Ascending aortic aneurysm repair with Hemashield	Successful	Ischemic brain lesion		
		Dacron Graft				
12	Ordenstein of statut constitutions	Left to state constitution and the second	Currentul	Calaura		
12	Occlusion of right carotid artery	Left-to-right carotid-carotid bypass	Successful	Seizure		
			HEAL	RT ABBOTT		
80 Skolk et al. Vace Endourseular Surg 2017 Oct-E1/71/470 470						
SKEIK	et ul vasc Elluovascular Surg. 2017 OCT;51(7):470-479					















